Geode Capital Management
KTTA icon

Geode Capital Management’s Pasithea Therapeutics KTTA Stock Holding History

Geode Capital Management’s Portfolio KTTA Stock Details KTTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$43.2K Sell
83,856
-20,129
-19% -$13.8K ﹤0.01% 4274
2026
Q1 		$77.1K Buy
103,985
+49,490
+91% +$41.4K ﹤0.01% 4198
2025
Q4 		$70.3K Buy
54,495
+29,020
+114% +$25.5K ﹤0.01% 4170
2025
Q3 		$18.3K Buy
+25,475
New +$18.6K ﹤0.01% 4421
2024
Q1 		– Sell
-6,256
Closed -$48.8K – 4625
2023
Q4 		$48.8K Hold
6,256
– – ﹤0.01% 4357
2023
Q3 		$60.1K Buy
6,256
+1,344
+27% +$14.7K ﹤0.01% 4375
2023
Q2 		$48.1K Hold
4,912
– – ﹤0.01% 4511
2023
Q1 		$38.2K Hold
4,912
– – ﹤0.01% 4579
2022
Q4 		$63K Sell
4,912
-18
-0.4% -$360 ﹤0.01% 4531
2022
Q3 		$124K Buy
4,930
+3,944
+400% +$92.6K ﹤0.01% 4464
2022
Q2 		$19K Buy
+986
New +$21K ﹤0.01% 4928

Other funds holding KTTA

CCC
Cable Car Capital San Francisco, California $4.66B AUM 77.16% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
AI
AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
PAP
Persistent Asset Partners Hong Kong $335M AUM 275.57% 1-Year Est. Return

Geode Capital Management's KTTA Position: Q2 2026 in Review

Geode Capital Management reduced its Pasithea Therapeutics (KTTA) stake by 19% in Q2 2026, selling an estimated $13.8K and leaving 83,856 shares worth $43.2K. The position accounts for ﹤0.01% of the portfolio, ranked #4274.

Geode Capital Management first reported a position in KTTA in Q2 2022 and has held it in 11 quarters since. The position peaked at $124K in Q3 2022. 25 funds tracked by Wall St. Rank hold KTTA as of Q2 2026.

  • Geode Capital Management held 83,856 shares of Pasithea Therapeutics worth $43.2K as of Q2 2026.
  • Geode Capital Management sold 20,129 Pasithea Therapeutics shares in Q2 2026, an estimated $13.8K.
  • Pasithea Therapeutics made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #4274 holding.
  • Geode Capital Management first reported a position in Pasithea Therapeutics in Q2 2022 and has held it in 11 quarters since.
  • Geode Capital Management's Pasithea Therapeutics position peaked at $124K in Q3 2022.
  • 25 funds tracked by Wall St. Rank held Pasithea Therapeutics as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.